Last updated on December 2015

Phase I Dose Escalation Study for BAY 1251152 in Patients With Advanced Cancer


Brief description of study

Determine the safety, tolerability, pharmacokinetics, maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D) of BAY 1251152 in patients with solid tumors and aggressive non-hodgkin's lymphoma (NHL).

Clinical Study Identifier: NCT02635672

Contact Investigators or Research Sites near you

Start Over